Aberrant activation of androgen receptor in a new neuropeptide- autocrine model of androgen-insensitive prostate cancer.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Cancer Statistics, 2007

Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · see citing works

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237 · see citing works

Focal adhesion kinase: in command and control of cell motility

Mitra, S. K., Hanson, D. R., & Schlaepfer, D. D. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1549 · Cited by 2,586 · see citing works

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

Cuttitta, F. F., Carney, D. N., Mulshine, J. L., Moody, T. W., FEDORKO, J., Fischler, A., & Minna, J. D. (1985) · Nature · doi:10.1038/316823a0 · Cited by 1,348 · see citing works

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938 · see citing works

Regulation of tyrosine kinase cascades by G-protein-coupled receptors

Luttrell, L. M., Daaka, Y., & Lefkowitz, R. J. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80023-4 · Cited by 688 · see citing works

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

Markwalder, R. V., & Reubi, J. C. (1999) · PubMed · Cited by 506 · see citing works

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Verweij, J., van Oosterom, A., Blay, J., Judson, I. R., Rodenhuis, S., der Graaf, W. V., Radford, J. A., Cesne, A. L., Hogendoorn, P. C. W., Paola, E. D. D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00836-5 · Cited by 401 · see citing works

Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells

Nam, S., Kim, D., Cheng, J. Q., Zhang, S., Lee, J., Buettner, R., Mirosevich, J., Lee, F. Y., & Jove, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1731 · Cited by 377 · see citing works

Regulation of androgen receptor activity by tyrosine phosphorylation.

Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · see citing works

Androgen Receptor Phosphorylation

Gioeli, D. G., Ficarro, S. B., Kwiek, J. J., Aaronson, D. S., Hancock, M., Catling, A. D., White, F. M., Christian, R. E., Settlage, R. E., Shabanowitz, J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204131200 · Cited by 355 · see citing works

Interleukin-6 regulation of prostate cancer cell growth.

Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269 · see citing works

Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities

Vashchenko, N. M., & Abrahamsson, P. (2004) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260 · see citing works

Neuroendocrine cells in tumour growth of the prostate.

Abrahamsson, P. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060503 · Cited by 247 · see citing works

G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo.

Nagata, A., Ito, M., Iwata, N., Kuno, J., Takano, H., Minowa, O., Chihara, K., Matsui, T., & Noda, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11825 · Cited by 234 · see citing works

Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model

Park, S. I., Zhang, J., Phillips, K. A., Araujo, J. C., Najjar, A. M., Volgin, A. Y., Gelovani, J. G., Kim, S., Wang, Z., & Gallick, G. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2997 · Cited by 233 · see citing works

Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.

Cox, M., Deeble, P. D., Lakhani, S., & Parsons, S. J. (1999) · PubMed · Cited by 224 · see citing works

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

Chang, Y.-M., Bai, L., Liu, S., Yang, J. C., Kung, H.-J., & Evans, C. P. (2008) · Oncogene · doi:10.1038/onc.2008.250 · Cited by 185 · see citing works

Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase

Lee, L., Guan, J., Qiu, Y., & Kung, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8385-8397.2001 · Cited by 184 · see citing works

Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs.

Sausville, E. A., Lebacq‐Verheyden, A., Spindel, E. R., Cuttitta, F. F., Gazdar, A. F., & Battey, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35956-2 · Cited by 181 · see citing works

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK

Lee, L., Louie, M. C., Desai, S. J., Yang, J. C., Chen, H.-W., Evans, C. P., & Kung, H.-J. (2004) · Oncogene · doi:10.1038/sj.onc.1207344 · Cited by 181 · see citing works

TRANSDIFFERENTIATION OF PROSTATE CANCER CELLS TO A NEUROENDOCRINE CELL PHENOTYPE IN VITRO AND IN VIVO

Burchardt, T., Burchardt, M., Chen, M., Cao, Y., TAILLE, A. D. L., SHABSIGH, A., Hayek, O., Dorai, T., & Buttyan, R. E. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68241-9 · Cited by 169 · see citing works

Androgen-induced recruitment of RNA polymerase II to a nuclear receptor–p160 coactivator complex

Louie, M. C., Yang, H. Q., Ma, A., Xu, W., Zou, J. X., Kung, H.-J., & Chen, H.-W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437824100 · Cited by 157 · see citing works

Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain

Chen, R., Kim, O., Li, M., Xiong, X., Guan, J., Kung, H.-J., Chen, H., Shimizu, Y., & Qiu, Y. (2001) · Nature Cell Biology · doi:10.1038/35074500 · Cited by 155 · see citing works

Etk, a Btk Family Tyrosine Kinase, Mediates Cellular Transformation by Linking Src to STAT3 Activation

Tsai, Y.-T., Su, Y., Fang, S.-S., Huang, T.-N., Qiu, Y., Jou, Y., Shih, H.-M., Kung, H.-J., & Chen, R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2043-2054.2000 · Cited by 141 · see citing works

Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins

Aprikian, A. G., Tremblay, L., Han, K., & Chevalier, S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970729)72:3 · Cited by 112 · see citing works

Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters

Dublin, E. A., Patel, N. K., Gillett, C., Smith, P., Peters, G. G., & Barnes, D. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980220)79:1 · Cited by 109 · see citing works

NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice

Jin, R. J., Wang, Y., Masumori, N., Ishii, K., Tsukamoto, T., Shappell, S. B., Hayward, S. W., Kasper, S., & Matusik, R. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3117 · Cited by 109 · see citing works

Neuropeptides as growth factors for normal and cancerous cells

Rozengurt, E. (2002) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00544-6 · Cited by 108 · see citing works

Tec/Bmx non‐receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Gα12/13

Mao, J., Xie, W., Yuan, H., Simon, M. I., Mano, H., & Wu, D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.19.5638 · Cited by 102 · see citing works

Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.

Guha, S., Lunn, J. A., Santiskulvong, C., & Rozengurt, E. (2003) · PubMed · Cited by 88 · see citing works

Expression of a Truncated Form of the c-Kit Tyrosine Kinase Receptor and Activation of Src Kinase in Human Prostatic Cancer

Paronetto, M. P., Farini, D., Sammarco, I., Maturo, G., Vespasiani, G., Geremia, R., Rossi, P., & Sette, C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63212-9 · Cited by 83 · see citing works

Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer

Gautschi, O. P., Tepper, C. G., Purnell, P. R., Izumiya, Y., Evans, C. P., Green, T. P., Desprez, P. Y., Lara, P. N., Gandara, D. R., Mack, P. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6403 · Cited by 81 · see citing works

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

Aprikian, A. G., Han, K., Chevalier, S., Bazinet, M., & Viallet, J. (1996) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0160297 · Cited by 77 · see citing works

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells

Gong, J.-Y., Zhu, J., Goodman, O. B., Pestell, R. G., Schlegel, P. N., Nanus, D. M., & Shen, R. (2006) · Oncogene · doi:10.1038/sj.onc.1209231 · Cited by 72 · see citing works

Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells

Thomas, S. M., Grandis, J. R., Wentzel, A. L., Gooding, W. E., Lui, V. W. Y., & Siegfried, J. M. (2005) · Neoplasia · doi:10.1593/neo.04454 · Cited by 69 · see citing works

Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer

Aprikian, A. G., Han, K., Guy, L., Landry, F., Bégin, L. R., & Chevalier, S. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(1998)8+ · Cited by 68 · see citing works

Expression of the gastrin releasing peptide gene in human small cell lung cancer

Lebacq‐Verheyden, A., Markowitz, S. D., Sausville, E. A., Krystal, G., Way, J. M., & Battey, J. F. (1988) · Lung Cancer · doi:10.1016/s0169-5002(88)80046-1 · Cited by 66 · see citing works

Gastrin-Releasing Peptide Is a Growth Factor for Human Neuroblastomas

Kim, S., Hu, W., Kelly, D. R., Hellmich, M. R., Evers, B. M., & Chung, D. H. (2002) · Annals of Surgery · doi:10.1097/00000658-200205000-00003 · Cited by 65 · see citing works

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells

Hiscox, S., Jordan, N., Morgan, L. D., Green, T. P., & Nicholson, R. I. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9065-y · Cited by 64 · see citing works

Inappropriate Activation of the Androgen Receptor by Nonsteroids: Involvement of the Src Kinase Pathway and Its Therapeutic Implications

Desai, S. J., Ma, A., Tepper, C. G., Chen, H.-W., & Kung, H.-J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2582 · Cited by 61 · see citing works

Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse

Dai, B., Kim, O., Xie, Y., Guo, Z., Xu, K., Wang, B., Kong, X., Melamed, J., Chen, H., Bieberich, C. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1364 · Cited by 58 · see citing works

Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase

Zheng, R., Iwase, A., Shen, R., Goodman, O. B., Sugimoto, N., Takuwa, Y., Lerner, D. J., & Nanus, D. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209586 · Cited by 53 · see citing works

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.

Cai, R. Z., Reile, H., Armatis, P. E., & Schally, A. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12664 · Cited by 52 · see citing works

Effects of bombesin and gastrin‐releasing peptide on human bronchial epithelial cells from a series of donors: Individual variation and modulation by bombesin analogs

Siegfried, J. M., Guentert, P. J., & Gaither, A. L. (1993) · The Anatomical Record · doi:10.1002/ar.1092360129 · Cited by 47 · see citing works

Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients

Wu, J. T., Astill, M. E., Liu, G. H., & Stephenson, R. A. (1998) · Journal of Clinical Laboratory Analysis · doi:10.1002/(sici)1098-2825(1998)12:1 · Cited by 45 · see citing works

Targeting gastrin-releasing peptide receptors for cancer treatment

Zhou, J., Chen, J., Mokotoff, M., & Ball, E. D. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200411000-00001 · Cited by 43 · see citing works

Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells

Jiang, X., Borgesi, R. A., McKnight, N. C., Kaur, R., Carpenter, C. L., & Balk, S. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703412200 · Cited by 36 · see citing works

Loss of imprinting of igf2 in renal-cell carcinomas

Oda, H., Kume, H., Shimizu, Y., Inoue, T., & Ishikawa, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980130)75:3 · Cited by 33 · see citing works

Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells

Han, K., Viallet, J., Chevalier, S., Zheng, W., Bazinet, M., & Aprikian, A. G. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970401)31:1 · Cited by 19 · see citing works

Tissue invasion and metastasis: Molecular, biological and clinical perspectives

Jiang, W. G., Sanders, A. J., Katoh, M., Ungefroren, H., Gieseler, F., Prince, M. E., Thompson, S. K., Zollo, M., Spano, D., Dhawan, P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.008 · Cited by 514 · see citing works

Androgen receptors in hormone-dependent and castration-resistant prostate cancer

Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 422 · see citing works

SRC: A Century of Science Brought to the Clinic

Aleshin, A. A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 212 · see citing works

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

Mayer, E. L., & Krop, I. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1834 · Cited by 197 · see citing works

Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors

Wu, Z., Chang, P., Yang, J. C., Chu, C.-Y., Wang, L., Chen, N., Ma, A.-H., Desai, S. J., Lo, S. H., Evans, C. P., et al. (2010) · Genes & Cancer · doi:10.1177/1947601909358324 · Cited by 165 · see citing works

Autophagy as a modulator and target in prostate cancer

Farrow, J. M., Yang, J. C., & Evans, C. P. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.196 · Cited by 163 · see citing works

Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer

Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150 · see citing works

SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

Fred Saad, C., & Lipton, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.11.005 · Cited by 126 · see citing works

Molecular pathways and targets in prostate cancer

Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 115 · see citing works

Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells.

Nadiminty, N., Lou, W., Sun, M., Chen, J., Yue, J., Kung, H.-J., Evans, C. P., Zhou, Q., & Gao, A. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3703 · Cited by 113 · see citing works

Interleukin-1β Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features

Liu, Q., Russell, M. R., Shahriari, K. S., Jernigan, D. L., Lioni, M., Garcia, F. U., & Fatatis, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3970 · Cited by 108 · see citing works

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106 · see citing works

Flavokawain B, a kava chalcone, induces apoptosis via up‐regulation of death‐receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth

Tang, Y., Li, X., Liu, Z., Simoneau, A. R., Xie, J., & Zi, X. (2010) · International Journal of Cancer · doi:10.1002/ijc.25210 · Cited by 93 · see citing works

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

Schenone, S., Brullo, C., Musumeci, F., & Botta, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499898 · Cited by 83 · see citing works

Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?

Grigore, A. D., Ben‐Jacob, E., & Farach‐Carson, M. C. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00037 · Cited by 76 · see citing works

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

Shi, X.-B., Ma, A., Xue, L., Li, M., Nguyen, H. G., Yang, J. C., Tepper, C. G., Gandour‐Edwards, R. F., Evans, C. P., Kung, H.-J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0795 · Cited by 74 · see citing works

Mitochondrial determinants of cancer health disparities

Choudhury, A. R., & Singh, K. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.001 · Cited by 74 · see citing works

Interleukin‐6 induces neuroendocrine differentiation (NED) through suppression of RE‐1 silencing transcription factor (REST)

Zhu, Y., Liu, C., Cui, Y., Nadiminty, N., Lou, W., & Gao, A. C. (2014) · The Prostate · doi:10.1002/pros.22819 · Cited by 72 · see citing works

SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

Rabbani, S. A., Valentino, M.-L., Arakelian, A., Ali, S., & Boschelli, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0962 · Cited by 63 · see citing works

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

Mounir, Z., Lin, F., Lin, V., Korn, J. M., Yu, Y., Valdez, R., Aina, O. H., Buchwalter, G., Jaffe, A. B., Korpal, M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.308 · Cited by 60 · see citing works

Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model

Yang, J. C., Bai, L., Yap, S. A., Gao, A. C., Kung, H.-J., & Evans, C. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1058 · Cited by 58 · see citing works

Targeting Tyrosine Kinases and Autophagy in Prostate Cancer

Kung, H.-J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0053-3 · Cited by 50 · see citing works

Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer

Brown, J. E., & Sim, S. (2010) · Neoplasia · doi:10.1593/neo.10610 · Cited by 48 · see citing works

Src: Marker or Actor in Prostate Cancer Aggressiveness

Vlaeminck‐Guillem, V., Gillet, G., & Rimokh, R. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00222 · Cited by 46 · see citing works

Activation of Rac1 Is Closely Related to Androgen-Independent Cell Proliferation of Prostate Cancer Cells Both in Vitro and in Vivo

Kobayashi, T., Inoue, T., Shimizu, Y., Terada, N., Maeno, A., Kajita, Y., Yamasaki, T., Kamba, T., Toda, Y., Mikami, Y., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0326 · Cited by 44 · see citing works

Gastrin-releasing peptide receptor signaling in the integration of stress and memory

Roesler, R., Kent, P., Luft, T., Schwartsmann, G., & Merali, Z. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.013 · Cited by 43 · see citing works

Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

Edwards, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003789388 · Cited by 42 · see citing works

Expression and function of gastrin‐releasing peptide ( GRP ) in normal and cancerous urological tissues

Ischia, J. J., Patel, O., Bolton, D. M., Shulkes, A., & Baldwin, G. S. (2014) · British Journal of Urology · doi:10.1111/bju.12594 · Cited by 42 · see citing works

Novel Role of Androgens in Mitochondrial Fission and Apoptosis

Choudhary, V., Kaddour‐Djebbar, I., Lakshmikanthan, V., Ghazaly, T., Thangjam, G. S., Sreekumar, A., Lewis, R. W., Mills, I. G., Bollag, W. B., & Kumar, M. V. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0445 · Cited by 41 · see citing works

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases

Loriot, Y., Massard, C., & Fizazi, K. S. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr573 · Cited by 37 · see citing works

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration

Bai, L., Yang, J. C., Ok, J.-H., Mack, P. C., Kung, H., & Evans, C. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26303 · Cited by 34 · see citing works

Androgen receptor: what we know and what we expect in castration-resistant prostate cancer

Cai, Z., Chen, W., Zhang, J., & Li, H. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1964-0 · Cited by 32 · see citing works

Role of targeted therapy in the treatment of advanced prostate cancer

Fizazi, K. S., Sternberg, C. N., Fitzpatrick, J. M., Watson, R. W. G., & Tabesh, M. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09236.x · Cited by 32 · see citing works

Lin28 Promotes Growth of Prostate Cancer Cells and Activates the Androgen Receptor

Tummala, R., Nadiminty, N., Lou, W., Zhu, Y., Gandour‐Edwards, R. F., Chen, H.-W., Evans, C. P., & Gao, A. C. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.03.011 · Cited by 31 · see citing works

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment

Aggarwal, R. R., & Ryan, C. J. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0216 · Cited by 31 · see citing works

Beyond resorption: osteoclasts as drivers of bone formation

Xiang, Q., Li, L., Ji, W., Gawlitta, D., Walboomers, X. F., & van den Beucken, J. J. J. P. (2024) · Cell Regeneration · doi:10.1186/s13619-024-00205-x · Cited by 29 · see citing works

Midkine is associated with neuroendocrine differentiation in castration‐resistant prostate cancer

Nordin, A., Wang, W., Welén, K., & Damber, J. (2012) · The Prostate · doi:10.1002/pros.22607 · Cited by 27 · see citing works

Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors

Lorusso, G., Rüegg, C., & Kuonen, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01231 · Cited by 26 · see citing works

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer

Fontana, F., & Limonta, P. (2021) · Cells · doi:10.3390/cells10051133 · Cited by 24 · see citing works

Emerging therapeutic strategies for Epstein–Barr virus+ post‐transplant lymphoproliferative disorder

Hatton, O. L., Martinez, O. M., & Esquivel, C. O. (2012) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2012.01656.x · Cited by 24 · see citing works

The relationship of neuroendocrine carcinomas to anti‐tumor therapies in TRAMP mice

Tang, Y., Wang, L., Goloubeva, O. G., Khan, M. A., Lee, D.-I., & Hussain, A. (2009) · The Prostate · doi:10.1002/pros.21026 · Cited by 22 · see citing works

Developments in Nonsteroidal Antiandrogens Targeting the Androgen Receptor

Liu, B., Su, L., Geng, J., Liu, J., & Zhao, G. (2010) · ChemMedChem · doi:10.1002/cmdc.201000259 · Cited by 21 · see citing works

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer

Pinto, F., Pértega‐Gomes, N., Vizcaino, J. R., Andrade, R. P., Cárcano, F. M., & Reis, R. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8499 · Cited by 21 · see citing works

A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer

Cheng, J., Moore, S., Gomez‐Galeno, J., Lee, D., Okolotowicz, K. J., & Cashman, J. R. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261040 · Cited by 19 · see citing works

Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.

Marcu, M. L., Radu, E., & Sajin, M. (2010) · PubMed · Cited by 18 · see citing works

Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer

Loriot, Y., Zoubeidi, A., & Gleave, M. E. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.008 · Cited by 15 · see citing works

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle

Berruti, A. (2010) · Research and Reports in Urology · doi:10.2147/oaju.s6573 · Cited by 15 · see citing works

Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC)

Jonnalagadda, B., Arockiasamy, S., & Krishnamoorthy, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118208 · Cited by 11 · see citing works

Gastrin‐releasing peptide: Predictor of castration‐resistant prostate cancer?

Heinrich, E., Probst, K. A., Michel, M. S., & Trojan, L. (2010) · The Prostate · doi:10.1002/pros.21280 · Cited by 9 · see citing works

Neuroendocrine Differentiation in Prostate Cancer

Franco, R., Chieffi, P., Perdonà, S., Facchini, G., & Caraglia, M. (2013) · Springer eBooks · doi:10.1007/978-94-007-7149-9_5 · Cited by 9 · see citing works

Uncommon Cancers of the Prostate

Tagawa, S. T., Akhtar, N. H., Robinson, B. D., & Beltran, H. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch4 · Cited by 9 · see citing works

Dasatinib and docetaxel in advanced prostate cancer

Lara, P. N., & Evans, C. P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70500-x · Cited by 7 · see citing works

Neuroendocrine Prostate Cancer

Beltran, H., Mosquera, J. M., & Rubin, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_22 · Cited by 6 · see citing works

[Neuroendocrine differentiation in prostate adenocarcinoma].

Ramírez-Balderrama, L. A., López-Briones, S., Daza-Benítez, L., Macías, M. H., López-Gaytán, T., & Pérez‐Vázquez, V. (2013) · PubMed · Cited by 6 · see citing works

Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer

Albain, K. S., Carey, L., Gradishar, W. J., Gralow, J. R., Lipton, A., Rugo, H. S., Tripathy, D., Peck, S. R., Abair, T., & Pegram, M. D. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.056 · Cited by 6 · see citing works

Emerging drugs for the treatment of bone metastasis

Pantano, F., Iuliani, M., Zoccoli, A., Fioramonti, M., Lisi, D. D., Fioroni, I., Ribelli, G., Santoni, M., Vincenzi, B., Tonini, G., et al. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1062876 · Cited by 5 · see citing works

PAWI-2: A novel inhibitor for eradication of cancer

Cheng, J., & Cashman, J. R. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02575-8 · Cited by 5 · see citing works

[Prostate cancer and apoptosis].

Mayora, A., & Arvelo, F. A. (2011) · PubMed · Cited by 5 · see citing works

Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer

Yashi, M., Nishihara, D., Yokoyama, M., Fuchizawa, H., Okazaki, A., Takei, K., Suzuki, I., Sakamoto, K., Kijima, T., Kobayashi, M., et al. (2022) · Cancer Reports · doi:10.1002/cnr2.1762 · Cited by 4 · see citing works

Neuroendocrine Prostate Cancer

Mosquera, J. M., Beltran, H., & Rubin, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05101-7 · Cited by 4 · see citing works

Targeting Bone Metastases: New Drugs for New Targets

Pantano, F., Zoccoli, A., Iuliani, M., Fioramonti, M., Lanzetta, G., Tonini, G., & Santini, D. (2013) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-013-9150-5 · Cited by 1 · see citing works

GRPR antagonists for prostate cancer—prospects and caveats

Roesler, R., & Schwartsmann, G. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.42-c1 · Cited by 1 · see citing works

Tyrosine Kinases in Prostate Cancer

Qiu, Y., & Deshmukh, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_11

Hormones and cancer: update from Tokyo 2010

Stingl, J., & Clarke, R. B. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.71

A Prominent Couple

Ratz (2017) · doi:10.26481/dis.20171215lr

Efeitos da exposição ao ambiente obesogênico em diferentes fases do desenvolvimento sobre a morfofisiologia da próstata de ratos Wistar

Pytlowanciv, E. Z. (2015) · doi:10.47749/t/unicamp.2015.959154

Current World Literature

(2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328339f31e

Efficacy of Signal Transduction Inhibition in Advanced Prostate Cancer

Staibano, S. (2013) · Springer eBooks · doi:10.1007/978-94-007-7149-9_15

L'analyse des mécanismes d'action d'Hsp27 a mis en évidence TCTP comme nouvelle cible thérapeutique des cancers de la prostate résistants à la castration.

Baylot, V. (2013) · doi:10.70675/47b727faz4a37z46c2z9f5dz29201400c39b

The GRPR signaling axis in cancer: Molecular mechanisms and oncogenic outcomes

Marcolin, J. C., Lichtenfels, M., Roesler, R., & de Farias, C. B. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112590

Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trial

Evans, C. P., Lara, P. N., Kung, H., & Yang, J. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.14542 · Cited by 11 · see citing works

Abstract 359: Neuropeptides promote castration-resistant prostate cancer through intracrine androgen biosynthesis

Yang, J. C., Kung, H., Gao, A. C., & Evans, C. P. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-359

Oncogenic activation of androgen receptor

Kung, H.-J., & Evans, C. P. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.06.002 · Cited by 52 · see citing works

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

Strohmeyer, D., R�ssing, C., Strauss, F., Bauerfeind, A., Kaufmann, O., & Loening, S. A. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000101)42:1 · Cited by 110 · see citing works

Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer

Case, T. C., Merkel, A. R., Ramirez-Solano, M. A., Liu, Q., Sterling, J. A. R., & Jin, R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101213 · Cited by 11 · see citing works